Karachi, February 27, 2025 – Citi Pharma Limited has announced the successful completion of its first-ever export to the MENA (Middle East and North Africa) Region, marking a significant milestone in its international expansion strategy.
(more…)Tag: Citi Pharma
-
Citi Pharma Pioneers API Manufacturing in Indonesia
Karachi, December 3, 2024 – Citi Pharma Limited has announced a landmark partnership with Mersi Farma, a leading pharmaceutical company based in Indonesia, to advance Active Pharmaceutical Ingredient (API) manufacturing and expand the nutraceutical market in Indonesia.
(more…) -
Citi Pharma Becomes Pakistan’s First Nutraceutical Exporter to US
Lahore, September 20, 2024 — In a historic achievement, Citi Pharma Limited has announced its entry into the U.S. market, becoming Pakistan’s first exporter of nutraceutical products to the United States. The announcement, made in a statement on Friday, marks a significant milestone in the country’s pharmaceutical industry.
(more…) -
Citi Pharma Pakistan Inks Supply Agreement with Indian Company
Karachi, July 2, 2024 – Citi Pharma Limited Pakistan has announced a landmark agreement with Murli Krishna Pharma Private Limited, an Indian company. The partnership, revealed on Tuesday, aims to enhance the pharmaceutical landscape in Pakistan through the supply of high-quality Active Pharmaceutical Ingredients (APIs) and products.
(more…) -
Citi Pharma Announces China-Based JV for API Expansion
Citi Pharma Limited, a key player in Pakistan’s pharmaceutical sector, has announced a significant joint venture (JV) with Hangzhou Newsea Technology Co. Ltd, aiming to bolster its Active Pharmaceutical Ingredients (API) manufacturing capabilities.
(more…) -
Citi Pharma declares 100% increase in half year profit
KARACHI: Citi Pharma Limited on Tuesday announced about 100 per cent increase in its net profit for the half year ended December 31, 2021.
The net profit of the company was Rs343 million for the half year ended December 31, 2021 as compared with Rs168 million in the same period of the last year.
READ MORE: PSX notifies listing of Citi Pharma
The company said that the net profit had witnessed significant rise in spite of the expenses incurred on the listing of the company during the period under review.
In the period under review, the net sales increased to Rs4.84 billion for the half year ended December 31, 2021 as compared with Rs2.63 billion in the corresponding period of the last year, showing a growth of 84 per cent.
Similarly, the gross profit increased to Rs701 million for the period under review as compared with Rs410 million in the same period of the last year.
READ MORE: Citi Pharma’s IPO oversubscribed; Rs2.32 billion raised in book building
On the quarter basis there is an increase of sales of the company from Rs1.99 billion to Rs2.85 billion and registered an increase of 43 per cent from the previous quarter.
The gross profit for the quarter increased to Rs405 million as compared with Rs296 million from the previous quarter and witnessed an increase of 37 per cent.
READ MORE: Citi Pharma’s IPO book building starts June 15
Net profit of the second quarter has improved to Rs261 million a compared with Rs81 million and registered an increase of 222 per cent on quarter basis, in the first quarter listing expense of Rs129 million was incorporated otherwise the profit could have been Rs210 million.
The company has also decided to increase the number of beds of the hospital from 50 to 200.
READ MORE: List of cities contributing tax above Rs1 billion
-
PSX notifies listing of Citi Pharma
KARACHI: Pakistan Stock Exchange (PSX) on Thursday notified the listing of Citi Pharma Limited (CPHL) and trading of company shares will commence on Friday July 09, 2021.
The PSX issued following information of all concerned:
1) Trading in the shares of the Company will commence on the Exchange’s Main Board from Friday, July 09, 2021 and shall be settled on T+2 basis. The first settlement date will be Tuesday, July 13, 2021.
2) The Market Lot of the Company will be 500 shares of Rs.10/- each.
3) The shares of the Company have already been declared an eligible security by the Central Depository Company of Pakistan Limited (CDC) and all the transactions shall be settled through the National Clearing Company of Pakistan Limited (NCCPL). NCCPL has assigned “CPHL” to the Company as their Company Code / Security Symbol.
4) The Opening Price of the shares of the Company will be PKR 32/- per share, as determined through the Book Building process when the Company was going public.
5) The Share Registrar of the Company is F.D. Registrar Services (Pvt.) Limited whose contact details are as follows:
Address: Office # 1705, 17th Floor, Saima Trade Tower-A, I.I. Chundrigar Road, Karachi
Phone: (021) 32271905
Website: www.fdregistrar.com
6) The Company will be quoted in the “Pharmaceuticals” Sector in the Daily Quotation of the Exchange.